血浆热休克蛋白90α预测肝细胞肝癌介入治疗预后的临床价值
该研究回顾性收集2017年8月至2018年12月在中国医学科学院肿瘤医院介入治疗科接受TACE治疗的96例HCC患者资料,分析血浆HSP90α水平与治疗反应及无进展生存时间的关系。多因素分析显示,TACE后HSP90α降低百分比是治疗应答和PFS的独立影响因素,提示其可能作为预测TACE疗效和预后的新型生物标志物。
要点
- 高HSP90α组较低HSP90α组肿瘤更大、甲胎蛋白更高、血管侵犯更多、BCLC分期更晚(均P<0.05)。
- TACE后4周,应答组HSP90α水平差值为(-32.20±22.79)ng/ml,无应答组为(7.20±51.94)ng/ml,差异有统计学意义(P<0.001)。
- TACE后HSP90α降低>50%者治疗应答的OR=86.831(P<0.001),PFS的HR=0.198(P<0.001)。
核心结论
- 血浆HSP90α可能作为一种新的生物标志物,用于预测HCC患者TACE治疗的疗效和无进展生存时间。
研究设计与样本
- 回顾性收集2017年8月至2018年12月在中国医学科学院肿瘤医院介入治疗科接受TACE治疗的96例HCC患者的病历资料。
- 采用χ2检验分析TACE前血浆HSP90α水平与临床病理特征的关系。
- 采用单因素和多因素logistic回归分析TACE治疗应答的影响因素。
- 采用单因素和多因素Cox回归分析TACE治疗后无进展生存时间(PFS)的影响因素。
主要发现
- 96例患者TACE治疗前血浆HSP90α水平为(99.70±66.61)ng/ml。
- 高HSP90α组(30例)比低HSP90α组(66例)肿瘤更大、甲胎蛋白更高、血管侵犯阳性者更多、BCLC分期更晚(均P<0.05)。
- TACE治疗4周后评估,应答组41例,无应答组55例;应答组与无应答组TACE前后HSP90α水平差值分别为(-32.20±22.79)ng/ml和(7.20±51.94)ng/ml,差异有统计学意义(P<0.001)。
- 96例患者的中位PFS为8.7个月。
关键数值与推荐
- 多因素logistic回归显示,Child-Pugh分级(OR=0.186,P=0.046)、血管侵犯(OR=0.132,P=0.025)、TACE后HSP90α降低百分比(25%~50%:OR=5.061,P=0.013;>50%:OR=86.831,P<0.001)是TACE治疗应答的独立影响因素。
- 多因素Cox回归显示,BCLC分期(B期:HR=2.804,P=0.008;C期:HR=4.628,P<0.001)和TACE后HSP90α降低百分比(25%~50%:HR=0.569,P=0.051;>50%:HR=0.198,P<0.001)是TACE治疗后PFS的独立影响因素。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the relationship between plasma heat shock protein 90α (HSP90α) levels and treatment response after four weeks and long-term prognosis after transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). Methods: The clinical data of HCC patients who underwent TACE in the Department of Interventional Radiology, Cancer Hospital of Chinese Academy of Medical Sciences from August 2017 to December 2018 were retrospectively collected. Chi-square tests were used to analyze the relationship between plasma HSP90α level and clinicopathological features before TACE treatment. Univariate and multivariate logistic regression analysis was used to analyze the influencing factors of TACE treatment response. Univariate and multivariate Cox regression analysis was used to analyze the influencing factors of progression-free survival (PFS) after TACE treatment. Results: The expression level of plasma HSP90α in 96 patients before TACE treatment was (99.70 ± 66.61) ng/ml. Compared with the low HSP90α group (n=66), the high HSP90α group (n=30) had larger tumors, higher alpha-fetoprotein enrichment, more positive vascular invasions, and more advanced Barcelona Clinic Liver Cancer (BCLC) stages (all P<0.05). After four weeks of TACE treatment, 41 patients in the response group and 55 patients in the non-response group were evaluated. The difference of HSP90α expression levels between the response group and the non-response group before and after TACE treatment was (-32.20±22.79) ng/ml and (7.20±51.94) ng/ml, respectively, and the difference was statistically significant (P<0.001). Multivariate logistic regression analysis showed that Child-Pugh classification (OR=0.186, P=0.046), vascular invasion (OR=0.132, P=0.025), and the percentage reduction of plasma HSP90α after TACE treatment (percentage reduction 25%-50%: OR=5.061, P=0.013; percentage reduction >50%: OR= 86.831, P<0.001) were independent influencing factors for the response to TACE treatment in HCC. The median PFS of the 96 patients was 8.7 months. Multivariate Cox regression analysis showed that BCLC stage (stage B: HR=2.804, P=0.008; stage C: HR=4.628, P<0.001) and the percentage reduction of plasma HSP90α after TACE treatment (percentage reduction 25%-50%: HR=0.569, P=0.051; percentage reduction >50%: HR=0.198, P<0.001) were independent influence factors for the PFS in these HCC patients after TACE treatment. Conclusion: Plasma HSP90α may represent a novel biomarker for predicting efficacy of TACE and PFS of patients with HCC. 目的: 探讨血浆热休克蛋白90α(HSP90α)与肝细胞肝癌(HCC)患者经动脉化疗栓塞(TACE)治疗反应及长期预后的关系。 方法: 收集2017年8月至2018年12月在中国医学科学院肿瘤医院介入治疗科进行TACE治疗的96例HCC患者的病历资料,采用χ2检验分析TACE治疗前血浆HSP90α水平与临床病理特征的关系,TACE治疗应答的影响因素分析采用单因素和多因素logistic回归分析,TACE治疗后患者无进展生存时间(PFS)的影响因素分析采用单因素和多因素Cox回归分析。 结果: 96例患者TACE治疗前的血浆HSP90α水平为(99.70±66.61)ng/ml。高HSP90α组(30例)比低HSP90α组(66例)肿瘤更大、甲胎蛋白更高、血管侵犯阳性者更多、巴塞罗那临床肝癌(BCLC)分期更晚(均P<0.05)。TACE治疗4周后评估,应答组41例,无应答组55例。应答组与无应答组患者TACE治疗前后HSP90α水平差值分别为(-32.20±22.79)ng/ml和(7.20±51.94)ng/ml,差异有统计学意义(P<0.001)。多因素logistic回归分析显示,Child-Pugh分级(OR=0.186,P=0.046)、血管侵犯(OR=0.132,P=0.025)、TACE治疗后血浆HSP90α降低百分比(25%~50%:OR=5.061,P=0.013;>50%:OR=86.831,P<0.001)是HCC TACE治疗应答的独立影响因素。96例患者的中位PFS为8.7个月。多因素Cox回归分析显示,BCLC分期(B期:HR=2.804,P=0.008;C期:HR=4.628,P<0.001)和TACE治疗后血浆HSP90α降低百分比(25%~50%:HR=0.569,P=0.051;>50%:HR=0.198,P<0.001)是TACE治疗后HCC患者PFS的独立影响因素。 结论: 血浆HSP90α作为一种新的生物标志物,可用于预测HCC患者TACE治疗的疗效和预后。.
引用
- Sun W, Li X. [The clinical value of heat shock protein 90α in predicting the prognosis of interventional therapy for hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 38418185. doi:10.3760/cma.j.cn112152-20231026-00262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。